KHK4323

KHK4323 is a small molecule drug that was developed by Kyowa Kirin for the treatment of immune system diseases, congenital disorders, and skin and musculoskeletal diseases, with a primary focus on atopic dermatitis. The drug was administered via intravenous or subcutaneous injection. Its mechanism of action remains unknown, as it does not have a novel or characterized target reported in public sources. Clinical development reached Phase 1 trials in healthy volunteers and subjects with atopic dermatitis; however, all known clinical studies were terminated early and the global development status is discontinued[1][2]. No approvals or brand names are associated with this compound.